Science News
from research organizations

Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma

Date:
July 12, 2011
Source:
JAMA and Archives Journals
Summary:
In a study examining eight eyes that were removed following intra-arterial chemotherapy (IAC) for treatment of retinoblastoma (a tumor of the retina of the eye), there was variable response of the tumor to therapy but also evidence of ocular complications.
Share:
       
FULL STORY

In a study examining eight eyes that were removed following intra-arterial chemotherapy (IAC) for treatment of retinoblastoma (a tumor of the retina of the eye), there was variable response of the tumor to therapy but also evidence of ocular complications, according to a report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals.

According to background information in the article, a new but somewhat controversial treatment for retinoblastoma (Rb) is IAC. In this type of therapy, chemotherapy is delivered directly to the eye and the surrounding area by administering the medication through the ophthalmic artery. "The main goal of this approach is to provide sufficient chemotherapy to eradicate the Rb and avoid the toxicities of systemic chemotherapy," explain the authors.

Ralph C. Eagle, Jr., M.D., from the Wills Eye Institute, Philadelphia, and colleagues examined eight eyes that had been treated with IAC but were later removed (enucleated). The enucleations were performed because the tumors were not responsive to therapy, or because other medical problems, such as a certain type of glaucoma, developed. An ophthalmic pathologist dissected and studied the eyes.

This examination demonstrated that the response to treatment ranged from minimal (one eye), to moderate (one eye), to extensive (four eyes) to complete regression (two eyes). However, a majority of the eyes also showed evidence of complications, including ischemia and atrophy of the retina, blood clots in blood vessels and foreign material within those clots.

"In summary, histopathology of eyes with Rb following IAC showed evidence of complete tumor regression in eyes in which there was clinical tumor regression and also confirmed viable tumor in those in which tumor was suspected clinically," report the authors. However, the authors also emphasize the importance of the discovery of blood vessel blockages and foreign material in the clots within those vessels. The researchers conclude, "We suggest that IAC for Rb be used with caution."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. C. Eagle, C. L. Shields, C. Bianciotto, P. Jabbour, J. A. Shields. Histopathologic Observations After Intra-arterial Chemotherapy for Retinoblastoma. Archives of Ophthalmology, 2011; DOI: 10.1001/archophthalmol.2011.223

Cite This Page:

JAMA and Archives Journals. "Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma." ScienceDaily. ScienceDaily, 12 July 2011. <www.sciencedaily.com/releases/2011/07/110712192232.htm>.
JAMA and Archives Journals. (2011, July 12). Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma. ScienceDaily. Retrieved May 24, 2015 from www.sciencedaily.com/releases/2011/07/110712192232.htm
JAMA and Archives Journals. "Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma." ScienceDaily. www.sciencedaily.com/releases/2011/07/110712192232.htm (accessed May 24, 2015).

Share This Page: